Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16738
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHolmes, Sophie E-
dc.contributor.authorEsterlis, Irina-
dc.contributor.authorMazure, Carolyn M-
dc.contributor.authorLim, Yen Ying-
dc.contributor.authorAmes, David-
dc.contributor.authorRainey-Smith, Stephanie R-
dc.contributor.authorFowler, Chris-
dc.contributor.authorEllis, Kathryn-
dc.contributor.authorMartins, Ralph N-
dc.contributor.authorSalvado, Olivier-
dc.contributor.authorDoré, Vincent-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorLaws, Simon M-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorPietrzak, Robert H-
dc.contributor.authorMaruff, Paul-
dc.contributor.authorAustralian Imaging, Biomarkers and Lifestyle (AIBL) Research Group-
dc.date2017-07-24-
dc.date.accessioned2017-07-27T03:19:58Z-
dc.date.available2017-07-27T03:19:58Z-
dc.date.issued2017-07-24-
dc.identifier.citationInternational Journal of Geriatric Pharmacy 2018; 33(2): 405-413en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16738-
dc.description.abstractOBJECTIVE: Depressive and anxiety symptoms are common in older adults, significantly affect quality of life, and are risk factors for Alzheimer's disease. We sought to identify the determinants of predominant trajectories of depressive and anxiety symptoms in cognitively normal older adults. METHOD: Four hundred twenty-three older adults recruited from the general community underwent Aβ positron emission tomography imaging, apolipoprotein and brain-derived neurotrophic factor genotyping, and cognitive testing at baseline and had follow-up assessments. All participants were cognitively normal and free of clinical depression at baseline. Latent growth mixture modeling was used to identify predominant trajectories of subthreshold depressive and anxiety symptoms over 6 years. Binary logistic regression analysis was used to identify baseline predictors of symptomatic depressive and anxiety trajectories. RESULTS: Latent growth mixture modeling revealed two predominant trajectories of depressive and anxiety symptoms: a chronically elevated trajectory and a low, stable symptom trajectory, with almost one in five participants falling into the elevated trajectory groups. Male sex (relative risk ratio (RRR) = 3.23), lower attentional function (RRR = 1.90), and carriage of the brain-derived neurotrophic factor Val66Met allele in women (RRR = 2.70) were associated with increased risk for chronically elevated depressive symptom trajectory. Carriage of the apolipoprotein epsilon 4 allele (RRR = 1.92) and lower executive function in women (RRR = 1.74) were associated with chronically elevated anxiety symptom trajectory. CONCLUSION: Our results indicate distinct and sex-specific risk factors linked to depressive and anxiety trajectories, which may help inform risk stratification and management of these symptoms in older adults at risk for Alzheimer's disease.en
dc.titleTrajectories of depressive and anxiety symptoms in older adults: a 6-year prospective cohort studyen
dc.typeJournal Articleen
dc.identifier.journaltitleInternational Journal of Geriatric Pharmacyen
dc.identifier.affiliationDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USAen
dc.identifier.affiliationThe Florey Institute, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationAcademic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, The University of Melbourne, Kew, Victoria, Australiaen
dc.identifier.affiliationNational Ageing Research Institute, Parkville, Victoria, Australiaen
dc.identifier.affiliationCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australiaen
dc.identifier.affiliationSir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australiaen
dc.identifier.affiliationThe Commonwealth Scientific and Industrial Research Organization, Canberra, Australiaen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationCooperative Research Centre for Mental Health, Carlton, Victoria, Australiaen
dc.identifier.affiliationSchool of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australiaen
dc.identifier.affiliationUS Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System, West Haven, CT, USAen
dc.identifier.affiliationCogstate Ltd., Melbourne, Victoria, Australiaen
dc.identifier.doi10.1002/gps.4761en
dc.type.contentTexten
dc.identifier.orcid0000-0002-4929-1932en
dc.identifier.orcid0000-0003-3910-2453en
dc.identifier.pubmedid28736899-
dc.type.austinJournal Articleen_US
local.name.researcherDoré, Vincent
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

36
checked on Nov 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.